PROTEUS Phase 3 Trial Finds Adding Second Perioperative Hormone Therapy to Prostatectomy Reduced Recurrence Risk in High-Risk Localized
A Phase 3 study found combining two hormone therapies before and after prostate removal produced better results than one hormone therapy in high-risk, early-stage cases. The findings may establish a third treatment path alongside surgery alone or radiation with hormone therapy.
news24.comThe PROTEUS trial found that combining two hormone therapies both before and after surgery was superior to just one hormone therapy before and after surgery in high-risk, early-stage prostate cancer cases, according to results reported May 31, 2026.
Patients with high-risk prostate cancer that has not spread typically have two standard treatment paths: surgical removal of the prostate or a combination of radiation therapy and hormone therapy. The trial tested whether adding a second hormone therapy around the time of surgery would improve outcomes compared with the single-hormone approach.
Emmanuel Antonarakis, a genitourinary medical oncologist at the University of Minnesota, called the results a “watershed moment” in prostate cancer. Antonarakis wrote an editorial in the New England Journal of Medicine about the PROTEUS trial. The article presenting the findings was written by Angus Chen, Cancer Reporter at STAT, and published from Chicago on May 31, 2026.
08. The PROTEUS trial is a Phase 3 clinical trial. Its results suggest that surgery with hormone therapy both before and after the operation may become available as a new option for high-risk, early-stage prostate cancer cases.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
New ScientistPhase 3 Trial Finds Daraxonrasib Extends Median Survival to 13 Months vs 7 Months for Chemotherapy in Second-Line Pancreatic Cancer
A 500-person study found the once-daily pill halted or reversed tumor progression in nearly one-third of patients versus 10 percent on chemotherapy. Median survival rose from less than seven months to roughly 13 months.
nypost.comBundibugyo Ebola Strain Shows High Survival Rate in DRC; Suspected Cases Reported in Brazil and Italy
Four nurses and one laboratory worker have recovered from Ebola caused by the Bundibugyo strain in the Democratic Republic of Congo. Suspected cases linked to travel from affected countries are under investigation in Brazil and Italy.
Wildfire Insured Losses Hit $54 Billion in 2025, Highest on Record
A new analysis published Sunday found that insured losses from wildfires worldwide hit at least $54 billion in 2025, the highest level on record. The Los Angeles fires and blazes in South Korea and Spain drove the total.